New combo therapy aims to silence hepatitis b virus
NCT ID NCT07069569
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests a new drug called AHB-137 given with either a hepatitis B vaccine or another medicine (pegylated interferon) in people with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the combination can lower the virus to undetectable levels and allow participants to safely stop their daily antiviral medication. About 200 adults aged 18-65 with HBeAg-negative hepatitis B will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.